High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report

Pancreatic neuroendocrine tumors (NETs), including poorly differentiated carcinomas (NECs), are rarely encountered. The majority of these tumors do not secrete excess hormones, but functioning NETs produce large amounts of vasoactive peptides and may cause carcinoid syndrome. Synthetic somatostatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Fraeyenhove, Frank, Meireson, Nathalie, Terriere, Luc, Willemsen, Paul, Kunnen, Jan, Mattelaer, Caroline, Van Acker, Frank, Schrijvers, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: March, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975754/
https://www.ncbi.nlm.nih.gov/pubmed/24707264
http://dx.doi.org/10.1159/000360732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975754/
https://www.ncbi.nlm.nih.gov/pubmed/24707264
http://dx.doi.org/10.1159/000360732

Ejemplares similares